Clinical Trial Update: SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SHR-A2102 in combination with Adebrelimab as neoadjuvant therapy for early-stage triple-negative breast cancer; the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A2102

Snippet

Sponsor: Henan Cancer Hospital | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING